Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on December 9, 2021, with the earliest event reported on that date. The filing addresses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Resignation of CFO: William Brown resigned as Chief Financial Officer, principal accounting officer, and principal financial officer, effective December 31, 2021. The resignation was voluntary to pursue other opportunities and was not the result of any disagreement with the Company.
- Appointment of New CFO: Richard I. Eisenstadt was appointed as Chief Financial Officer, effective December 31, 2021. He will also serve as principal accounting officer and principal financial officer.
Compensation, Outlook, and Risks
The filing details the employment agreement for the new CFO, Richard I. Eisenstadt, dated December 10, 2021. Key terms include:
- Base Salary: $425,000 annually.
- Annual Bonus: Target of 40% of base salary, contingent on performance goals.
- Signing Bonus: $120,000, subject to repayment if employment is terminated for "Cause" or resignation without "Good Reason" on or before December 31, 2022.
- Equity Grants:
- Option Grant: 150,000 shares at fair market value. 25% vests on December 31, 2022; the remainder vests ratably over 36 months.
- RSU Grant: 50,000 restricted stock units. 25% vests on December 31, 2022; the remainder vests in equal annual installments over the following three years.
- Severance Provisions:
- Standard Termination: If terminated without Cause or resigns for Good Reason, Mr. Eisenstadt receives 12 months of salary and 12 months of COBRA coverage.
- Change in Control: If terminated without Cause or resigns for Good Reason within 12 months of a Change in Control, he receives 12 months of salary plus the target annual bonus, 12 months of COBRA, and full acceleration of unvested equity awards.
The filing states there are no family relationships between Mr. Eisenstadt and any director or executive officer, and no reportable transactions under Item 404(a) of Regulation S-K exist other than the employment agreement.
Investor Verification Checklist
- Verify the effective date of the CFO transition (December 31, 2021) and the interim financial oversight arrangements.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the impact of the $120,000 signing bonus and equity grants on the company's near-term cash flow and dilution.
- Monitor the press release (Exhibit 99.1) for any additional context regarding the leadership change.